Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2014

Open Access 01-12-2014 | Research article

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study

Authors: Joakim Hertze, Katarina Nägga, Lennart Minthon, Oskar Hansson

Published in: BMC Neurology | Issue 1/2014

Login to get access

Abstract

Background

The Insulin-like Growth Factor (IGF)-related system is implicated in neuroregeneration and cell repair, as well as regulating lifespan. IGF-II, one component of this system, has also been found to affect memory functions in a rat model. In this study we explored changes in the IGF-related system in patients with Alzheimer’s disease (AD), including changes in IGF-II levels.

Methods

We measured blood plasma and cerebrospinal fluid (CSF) levels of IGF-I, IGF-II, IGFBP-2 and IGFBP-3 in 72 healthy controls and 92 patients with AD.

Results

We found significantly lower blood plasma levels of IGF-II and IGFBP-3 in patients with AD, compared with controls. The levels of IGF-II and IGFBP-2 were significantly elevated in the CSF from patients with AD. We also found correlations between established CSF biomarkers for AD (tau and P-tau) and components of the IGF system.

Conclusions

CSF and blood plasma levels of IGF-II and some of its binding proteins are changed in patients with AD. Further investigation into this area may unravel important clues to the nature of this disease.
Appendix
Available only for authorised users
Literature
1.
Sicras A, Rejas J, Arco S, Flores E, Ortega G, Esparcia A, Suárez A, Gordillo MJ: Prevalence, resource utilization and costs of vascular dementia compared to Alzheimer's dementia in a population setting. Dement Geriatr Cogn Disord. 2005, 19 (5–6): 305-315.CrossRefPubMed
2.
Puglielli L: Aging of the brain, neurotrophin signaling, and Alzheimer’s disease: is IGF1-R the common culprit?. Neurobiol Aging. 2008, 29: 795-811.CrossRefPubMed
3.
Zetterberg H, Blennow K, Hanse E: Amyloid beta and APP as biomarkers for Alzheimer's disease. Exp Gerontol. 2010, 45 (1): 23-29.CrossRefPubMed
4.
D'Ercole AJ, Ye P, Calikoglu AS, Gutierrez-Ospina G: The role of the insulin-like growth factors in the central nervous system. Mol Neurobiol. 1996, 13: 227-255.CrossRefPubMed
5.
6.
Russo VC, Gluckman PD, Feldman EL, Werther GA: The insulin-like growth factor system and its pleiotropic functions in brain. Endoc Rev. 2005, 26: 916-943.CrossRef
7.
Chen DY, Stern SA, Garcia-Osta A, Saunier-Rebori B, Pollonini G, Bambah-Mukku D, Blitzer RD, Alberini CM: A critical role for IGF-II in memory consolidation and enhancement. Nature. 2011, 469: 491-497.CrossRefPubMedPubMedCentral
8.
Feldman EL, Sullivan KA, Kim B, Russell JW: Insulin-like growth factors regulate neuronal differentiation and survival. Neurobiol Dis. 1997, 4 (3–4): 201-214.CrossRefPubMed
9.
Hawkes C, Kar S: The insulin-like growth factor-II/mannose-6-phosphate receptor: structure, distribution and function in the central nervous system. Brain Res Rev. 2004, 44: 117-140.CrossRefPubMed
10.
11.
Lee WH, Michels KM, Bondy CA: Localization of insulin-like growth factor binding protein-2 messenger RNA during postnatal brain development: correlation with insulin-like growth factors I and II. NSC. 1993, 53: 251-265.
12.
Johansson P, Åberg D, Johansson J-O, Mattsson N, Hansson O, Ahrén B, Isgaard J, Åberg ND, Blennow K, Zetterberg H, Wallin A, Svensson J: Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. Psychoneuroendocrinology. 2013, 38: 1729-1737.CrossRefPubMed
13.
Firth SM, Baxter RC: Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002, 23: 824-854.CrossRefPubMed
14.
15.
Garcia-Fernandez M, Sierra I, Puche JE, Guerra L, Castilla-Cortazar I: Liver mitochondrial dysfunction is reverted by insulin-like growth factor II (IGF-II) in aging rats. J Transl Med. 2011, 9: 123-CrossRefPubMedPubMedCentral
16.
van Dam PS, Aleman A: Insulin-like growth factor-I, cognition and brain aging. Eur J Pharmacol. 2004, 490: 87-95.CrossRefPubMed
17.
Watanabe T, Miyazaki A, Katagiri T, Yamamoto H, Idei T, Iguchi T: Relationship between serum insulin-like growth factor-1 levels and Alzheimer's disease and vascular dementia. J Am Geriatr Soc. 2005, 53: 1748-1753.CrossRefPubMed
18.
van Dam PS, Aleman A, de Vries WR, Deijen JB, van der Veen EA, de Haan EH, Koppeschaar HP: Growth hormone, insulin-like growth factor I and cognitive function in adults. Growth Horm IGF Res. 2000, 10 (Suppl B): S69-S73.CrossRefPubMed
19.
Aleman A, Torres-Alemán I: Circulating insulin-like growth factor I and cognitive function: neuromodulation throughout the lifespan. Prog Neurobiol. 2009, 89: 256-265.CrossRefPubMed
20.
Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM: Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis. 2005, 8: 247-268.PubMed
21.
Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM: Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease–is this type 3 diabetes?. J Alzheimers Dis. 2005, 7: 63-80.PubMed
22.
Kita Y, Ago Y, Takano E, Fukada A, Takuma K, Matsuda T: Galantamine increases hippocampal insulin-like growth factor 2 expression via α7 nicotinic acetylcholine receptors in mice. Psychopharmacology (Berl). 2013, 225: 543-551.CrossRef
23.
Cohen E, Paulsson JF, Blinder P, Burstyn-Cohen T, Du D, Estepa G, Adame A, Pham HM, Holzenberger M, Kelly JW, Masliah E, Dillin A: Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell. 2009, 139: 1157-1169.CrossRefPubMedPubMedCentral
24.
Freude S, Hettich MM, Schumann C, Stöhr O, Koch L, Köhler C, Udelhoven M, Leeser U, Müller M, Kubota N, Kadowaki T, Krone W, Schröder H, Brüning JC, Schubert M: Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J. 2009, 23: 3315-3324.CrossRefPubMed
25.
Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I: Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med. 2002, 8: 1390-1397.CrossRefPubMed
26.
Pan W, Kastin AJ: Interactions of IGF-1 with the blood–brain barrier in vivo and in situ. Neuroendocrinology. 2000, 72: 171-178.CrossRefPubMed
27.
Niikura T, Hashimoto Y, Okamoto T, Abe Y, Yasukawa T, Kawasumi M, Hiraki T, Kita Y, Terashita K, Kouyama K, Nishimoto I: Insulin-like growth factor I (IGF-I) protects cells from apoptosis by Alzheimer's V642I mutant amyloid precursor protein through IGF-I receptor in an IGF-binding protein-sensitive manner. J Neurosci. 2001, 21: 1902-1910.PubMed
28.
Doré S, Kar S, Quirion R: Insulin-like growth factor I protects and rescues hippocampal neurons against beta-amyloid- and human amylin-induced toxicity. Proc Natl Acad Sci USA. 1997, 94: 4772-4777.CrossRefPubMedPubMedCentral
29.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R. 1987, Arlington: American Psychiatric Association
30.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimerʼs disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimerʼs Disease. Neurology. 1984, 34: 939-944.CrossRefPubMed
31.
Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P, European Task Force on Age-Related White Matter Changes: A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001, 32: 1318-1322.CrossRefPubMed
32.
Blennow K, Hampel H, Weiner M, Zetterberg H: Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010, 6: 131-144.CrossRefPubMed
33.
Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O: Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. J Alzheimers Dis. 2010, 21: 1119-1128.PubMed
34.
Thissen JP, Underwood LE, Ketelslegers JM: Regulation of insulin-like growth factor-I in starvation and injury. Nutr Rev. 1999, 57: 167-176.CrossRefPubMed
35.
Tham A, Nordberg A, Grissom FE, Carlsson-Skwirut C, Viitanen M, Sara VR: Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J Neural Transm Gen Sect. 1993, 5: 165-176.CrossRef
36.
Salehi Z, Mashayekhi F, Naji M: Insulin like growth factor-1 and insulin like growth factor binding proteins in the cerebrospinal fluid and serum from patients with Alzheimer's disease. Biofactors. 2008, 33: 99-106.CrossRefPubMed
37.
Vardy ERLC, Rice PJ, Bowie PCW, Holmes JD, Grant PJ, Hooper NM: Increased circulating insulin-like growth factor-1 in late-onset Alzheimer's disease. J Alzheimers Dis. 2007, 12: 285-290.PubMed
38.
Duron E, Funalot B, Brunel N, Coste J, Quinquis L, Viollet C, Belmin J, Jouanny P, Pasquier F, Treluyer J-M, Epelbaum J, Le Bouc Y, Hanon O: Insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Alzheimer's disease. J Clin Endocrinol Metab. 2012, 97: 4673-4681.CrossRefPubMed
39.
Delrieu J, Ousset P-J, Caillaud C, Vellas B: ‘Clinical trials in Alzheimer‘s disease’: immunotherapy approaches. J Neurochem. 2012, 120 (Suppl 1): 186-193.CrossRefPubMed
40.
Moloney AM, Griffin RJ, Timmons S, O’Connor R, Ravid R, O’Neill C: Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging. 2010, 31: 224-243.CrossRefPubMed
41.
Gasparini L, Xu H: Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci. 2003, 26: 404-406.CrossRefPubMed
42.
de la Monte SM, Wands JR: Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis. 2005, 7: 45-61.PubMed
43.
Talbot K, Wang H-Y, Kazi H, Han L-Y, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE: Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012, 122: 1316-1338.CrossRefPubMedPubMedCentral
44.
Hoeflich A, Wu M, Mohan S, Föll J, Wanke R, Froehlich T, Arnold GJ, Lahm H, Kolb HJ, Wolf E: Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain. Endocrinology. 1999, 140: 5488-5496.CrossRefPubMed
45.
Kurmasheva RT, Houghton PJ: IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta. 2006, 1766: 1-22.PubMed
46.
Madathil SK, Evans HN, Saatman KE: Temporal and regional changes in IGF-1/IGF-1R signaling in the mouse brain after traumatic brain injury. J Neurotrauma. 2010, 27: 95-107.CrossRefPubMed
47.
Saatman KE, Contreras PC, Smith DH, Raghupathi R, McDermott KL, Fernandez SC, Sanderson KL, Voddi M, McIntosh TK: Insulin-like growth factor-1 (IGF-1) improves both neurological motor and cognitive outcome following experimental brain injury. Exp Neurol. 1997, 147: 418-427.CrossRefPubMed
48.
Devesa J, Reimunde P, Devesa P, Barberá M, Arce V: Growth hormone (GH) and brain trauma. Horm Behav. 2013, 63: 331-344.CrossRefPubMed
49.
Blennow K, Hampel H: CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003, 2: 605-613.CrossRefPubMed
50.
Buerger K, Ewers M, Pirttilä T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H: CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006, 129: 3035-3041.CrossRefPubMed
51.
Gómez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT: Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997, 41: 17-24.CrossRefPubMed
Metadata
Title
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Authors
Joakim Hertze
Katarina Nägga
Lennart Minthon
Oskar Hansson
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2014
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-14-64

Other articles of this Issue 1/2014

BMC Neurology 1/2014 Go to the issue

Research article

Heart rate changes in partial seizures: analysis of influencing factors among refractory patients

Research article

Brainstem infarcts predict REM sleep behavior disorder in acute ischemic stroke

Research article

Clinical baseline factors predict response to natalizumab: their usefulness in patient selection

Research article

Quality of life in purely ocular myasthenia in Japan

Case report

Creutzfeldt-Jakob disease mimicking autoimmune encephalitis with CASPR2 antibodies

Research article

Factors associated with fear of falling in people with Parkinson’s disease